Background: The newly emerged coronavirus SARS-CoV-2, first reported in December
2019, has infected about five and a half million people globally and resulted in nearly 9063264
deaths until the 24th of June 2020. Nevertheless, the highly contagious virus has instigated an unimaginably
rapid response from scientific and medical communities.
Objectives: Pioneering research on molecular mechanisms underlying the viral transmission, molecular
pathogenicity, and potential treatments will be highlighted in this review. The development of antiviral
drugs specific to SARS-CoV-2 is a complicated and tedious process. To accelerate scientific
discoveries and advancement, researchers are consolidating available data from associated coronaviruses
into a single pipeline, which can be readily made available to vaccine developers.
Methods: In order to find studies evaluating the COVID-19 virus epidemiology, repurposed drugs
and potential vaccines, web searches and bibliographical bases have been used with keywords that
matches the content of this review.
Results: The published results of SARS-CoV-2 structures and interactomics have been used to identify
potential therapeutic candidates. We illustrate recent publications on SARS-CoV-2, concerning
its molecular, epidemiological, and clinical characteristics, and focus on innovative diagnostics technologies
in the production pipeline. This objective of this review is to enhance the comprehension of
the unique characteristics of SARS-CoV-2 and strengthen future control measures.
Lay Summary: An innovative analysis is evaluating the nature of the COVID-19 pandemic. The aim
is to increase knowledge of possible viral detection methods, which highlights several new technology
limitations and advantages. We have assessed some drugs currently for patients (Lopinavir, Ritonavir,
Anakinra and Interferon beta 1a), as the feasibility of COVID-19 specific antivirals is not
presently known. The study explores the race toward vaccine development and highlights some significant
trials and candidates in various clinical phases. This research addresses critical knowledge
gaps by identifying repurposed drugs currently under clinical trials. Findings will be fed back rapidly
to the researchers interested in COVID 19 and support the evidence and potential of possible therapeutics
and small molecules with their mode of action.